Clinical Trial Update: Japan PhI/II of GSK2118436 and GSK1120212 Combination in Subjects With BRAF V600E/K Mutation Positive Advanced Solid Tumors (Phase I Part) or Cutaneous Melanoma (Phase II Part) [Phase 2]

View source ↗

Summary

Phase I/II trial update from Japan evaluating the dabrafenib and trametinib combination in patients with BRAF V600 mutation-positive advanced solid tumors or cu…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cutaneous Melanoma
• Solid Tumors

Drugs mentioned

• Dabrafenib (Dabrafenib)
• Trametinib (trametinib)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Solid Tumours | Phase 2 | Status: COMPLETED | Results posted: 2015-10-02